Early Detection of Urinary Proteome Biomarkers for Effective Early Treatment of Pulmonary Fibrosis in a Rat Model
- 20 November 2017
- journal article
- research article
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 11 (11-12)
Abstract
Scope: Pulmonary fibrosis (PF) is a progressive and devastating lung disease. With limited effective treatments available in the late stage, PF has a very poor prognosis. Molecular biomarkers are highly desired for PF, especially for its early phase.Materials and methods: Urine is a good biomarker source, and accumulates systemic changes in the body especially in the early‐stage of diseases. In this study, a bleomycin (BLM)‐induced rat model is used to mimic PF. Using labeled proteome quantitation, some urinary proteins are identified as candidate biomarkers of PF for early detection and disease monitoring. Then, prednisone treatment is administered at different phases of fibrosis.Results: Our results suggested that urine proteins could enable early detection and monitoring of both disease progression and treatment efficacy in the BLM‐induced PF model. Early prednisone treatment effectively inhibited pulmonary fibrosis, whereas the same treatment at a later phase had very limited effects. Meanwhile, five proteins showed the potential for monitoring therapeutic response.Conclusion: Urinary proteomics has been underutilized in respiratory diseases. These findings will improve our understanding of the pathogenesis of PF and accelerate biomarker discovery in respiratory diseases.Keywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7173264, 7172076)
- Beijing Normal University (11100704)
This publication has 41 references indexed in Scilit:
- XIST/miR-139 axis regulates bleomycin (BLM)-induced extracellular matrix (ECM) and pulmonary fibrosis through β-cateninOncotarget, 2017
- Physiological conditions can be reflected in human urine proteome and metabolomeExpert Review of Proteomics, 2015
- A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin‐induced pulmonary fibrosisProteomics, 2015
- Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11The Lancet Respiratory Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- The identification of tuberculosis biomarkers in human urine samplesEuropean Respiratory Journal, 2014
- Urine—an untapped goldmine for biomarker discovery?Science China Life Sciences, 2013
- PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discoveryEuropean Respiratory Review, 2013
- The rising incidence of idiopathic pulmonary fibrosis in the UKThorax, 2011
- Urine Thrombomodulin in Patients With Idiopathic Pulmonary FibrosisChest, 1998